NVS 250417 95.00P(NVS250417P95000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

NVS250417P95000

Watchlist

0.40
+0.28+233.33%

15min DelayClose Apr 4 15:59 ET

0.40High0.34Low

Intraday

5D
Daily

News

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
BenzingaApr 3 12:10 ET
Sector Update: Health Care Stocks Lean Lower Premarket Thursday
MT NewswiresApr 3 09:13 ET
Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)
TipRanksApr 3 07:36 ET · Ratings
Reported Earlier, Novartis Gains FDA Accelerated Approval For Vanrafia, The First Selective ETA Receptor Antagonist For Proteinuria Reduction In IgA Nephropathy
BenzingaApr 3 02:21 ET
Novartis' Vanrafia Receives Accelerated Approval From US FDA
MT NewswiresApr 2 23:30 ET
TG Therapeutics Rises After Trial Setback for High Dose Version of Roche's MS Drug
Seeking AlphaApr 2 12:15 ET

Comments

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

$Novartis AG (NVS.US)$
Groundbreaking FDA Approval: Novartis Drug Shows 36% Reduction in Severe Kidney Disease Symptoms

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G

$Novartis AG (NVS.US)$
Breakthrough: Novartis Scores Historic FDA Approval for Rare Kidney Disease Treatment

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G

$Novartis AG (NVS.US)$ Only u are dropping

$Novartis AG (NVS.US)$ Finally moving up before Dividend

$Novartis AG (NVS.US)$ why this stock keeps falling despite so many good news. Can someone enlighten pls

Read more